Skip to main content

Table 7 Overview of the impact of varying the efficacy against CIN2+ outcomes associated with non-vaccine types

From: Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Cross protection efficacy (%) Difference in cross-protection efficacy Difference in undiscounted lifetime cases of cancer Difference in discounted lifetime healthcare cost Difference in discounted lifetime QALY Discounted incremental cost per QALY Gained
  (A – B) (A – B) (A – B) (A – B)  
A: 45.7; B: 51.9 −6.2 8 $628 335 −115 B Dominates A
A: 45.7; B: 32.5 13.2 −18 $28 868 −62 B Dominates A
A: 68.4; B: 51.9 16.5 −22 -$83 640 −52 $1 611
A: 82.4; B: 51.9 30.5 −42 -$530 970 −12 $43 499
Base Case:
A: 68.4; B: 32.5
35.9 −48 -$683 107 1 A Dominates B
A: 45.7; B: 6.0 39.7 −52 -$771 520 10 A Dominates B
A: 82.4; B: 32.5 49.9 −67 -$1 130 437 41 A Dominates B
A: 68.4; B: 6.0 62.4 −83 -$1 483 495 73 A Dominates B
A: 82.4; B: 6.0 76.4 −102 -$1 930 825 113 A Dominates B
  1. Cross-protection efficacy: Efficacy against CIN2/3+ outcomes attributed to non-vaccine oncogenic types.
  2. A - Vaccine A: HPV-16/18 AS04-adjuvanted vaccine.
  3. B - Vaccine B: HPV-6/11/16/18 vaccine.
  4. QALY – Quality Adjusted Life Year.